**Title:** Healthify Eyes Rapid Growth with GLP-1 Weight-Loss Drugs
**Meta Description:** Healthify anticipates a surge in demand for GLP-1 weight-loss drugs in India, aiming for 20% revenue growth while addressing side effects and weight maintenance.
**URL Slug:** healthify-glp1-weight-loss-drugs-india
—
**Healthify Eyes Rapid Growth with GLP-1 Weight-Loss Drugs**
Healthify, a healthtech company, is poised to capitalize on the increasing popularity of GLP-1 weight-loss medications in India. Tushar Vashisht, the founder and CEO, predicts that as prices decrease, the adoption of these drugs will accelerate significantly. The company is integrating these medications with lifestyle coaching to enhance their effectiveness and support users in maintaining weight loss after treatment.
The firm is expanding its offerings to include GLP-1 drugs like Ozempic and Mounjaro, which are primarily used for managing type 2 diabetes and obesity. Vashisht shared that Healthify expects revenue from its GLP-1 companion programs to surpass its main revenue stream within the next three to four years. Originally launched as a calorie and nutrition-tracking app, Healthify is now focusing on the anticipated surge in demand for weight-loss drugs in India.
Vashisht stated, “Adoption of the drugs will happen very rapidly as prices come down. What we are hopeful to do is to pioneer the companion solution.” He acknowledged that while immediate adoption may be gradual, he envisions a future where every hospital offers a medical weight-loss program, emphasizing the necessity of lifestyle support for all users.
Healthify has launched programs that combine GLP-1 medications with lifestyle coaching, catering to both new users and those already on the drugs. The company has partnered with online pharmacy Tata 1mg to provide these medications and diagnostic services. Their three-month program, priced at ₹65,000, includes 12 doses of Mounjaro, along with access to a nutritionist, trainer, dietician, and a GI kit, all tracked through the Healthify app. Longer programs are also available, with six-month and one-year options costing ₹80,000 and ₹1 lakh, respectively.
After achieving its first profitable quarter in India from January to March, Healthify aims to sustain this momentum throughout the year. Vashisht expressed optimism about the fiscal year, stating, “The idea is to continue to stay profitable. We’re excited about this fiscal year in India being our first which is going to be profitable.” The company is targeting a 20% year-on-year revenue growth, with GLP-1 drugs being a crucial factor in reaching this goal.
Healthify is also addressing two significant challenges associated with weight-loss drugs: the gastrointestinal side effects of GLP-1 medications and the common issue of weight regain after discontinuation. The company recognizes the need for lifestyle interventions to help users maintain their weight loss.
In addition to its operations in India, Healthify entered the U.S. market last year and plans to expand its presence there in the coming months.
**FAQ**
**What are GLP-1 weight-loss drugs?**
GLP-1 weight-loss drugs are medications that mimic the action of the glucagon-like peptide-1 hormone, helping to regulate appetite and glucose levels, and are used to treat obesity and type 2 diabetes.